Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
89.43 EUR | -0.48% | -0.64% | -0.38% |
May. 27 | Sanofi Gets US FDA’s Priority Review for Expanded Use of Blood Cancer Drug Sarclisa | MT |
May. 27 | Sanofi: FDA grants priority review in myeloma | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.38% | 122B | |
+38.51% | 727B | |
+31.06% | 594B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+13.89% | 243B | |
+7.93% | 205B | |
-5.52% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Ligand Pharmaceuticals Acquires Royalty on Sanofi's Diabetes Therapy for $20 Million in Cash